Stockscreener 앱 받기
26.53
3.49%
-0.96
시간 외 거래:
26.31
-0.22
-0.83%
전일 마감가:
$27.49
열려 있는:
$27.52
하루 거래량:
1.28M
Relative Volume:
0.94
시가총액:
$5.40B
수익:
-
순이익/손실:
$-464.20M
주가수익비율:
-9.8908
EPS:
-2.6823
순현금흐름:
$-423.09M
1주 성능:
-8.71%
1개월 성능:
-9.45%
6개월 성능:
+11.99%
1년 성능:
+83.47%
1일 변동 폭
$26.06
$27.62
1주일 범위
$26.06
$29.54
52주 변동 폭
$13.79
$30.16
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-410-3120
주소
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
26.53 | 5.60B | 0 | -464.20M | -423.09M | -2.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Bernstein | Mkt Perform |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | 개시 | Truist | Hold |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
Immunovant Inc stock (US45258Q1058): earnings countdown and biotech hopes raise volatility - AD HOC NEWS
Immunovant stock (US45258Q1058): investors eye upcoming earnings date and autoimmune pipeline - AD HOC NEWS
David Einhorn's Immunovant Inc(IMVT) Holding History - GuruFocus
TradingKey - TradingKey
How (IMVT) Movements Inform Risk Allocation Models - Stock Traders Daily
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN
Immunovant stock hits 52-week high of $30.1 - Investing.com India
Immunovant stock hits 52-week high of $30.1 By Investing.com - Investing.com South Africa
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026 - The Manila Times
700,464 Shares in Immunovant, Inc. $IMVT Bought by Jennison Associates LLC - MarketBeat
Immunovant, Inc. $IMVT Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Trading Systems Reacting to (IMVT) Volatility - Stock Traders Daily
Immunovant's treatment for eye disease fails in late-stage trials - MSN
Immunovant director Robert Susman sells $67,979 in stock By Investing.com - Investing.com Nigeria
Immunovant director Robert Susman sells $67,979 in stock - Investing.com
Immunovant (IMVT) director’s 10b5-1 sale leaves 36,394 shares held - Stock Titan
Immunovant | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
[144] Immunovant, Inc. SEC Filing - Stock Titan
Immunovant falls on late-stage trial setback for TED therapy - MSN
Wells Fargo Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Wall Street analysts predict a 55.04% upside in Immunovant (IMVT): Here's what you should know - MSN
Immunovant CFO Tiago Girao sells $763,011 in company stock By Investing.com - Investing.com Australia
Immunovant (NASDAQ:IMVT) CFO Tiago Girao Sells 25,760 Shares - MarketBeat
Immunovant (NASDAQ:IMVT) CTO Sells $81,573.48 in Stock - MarketBeat
Immunovant CFO Tiago Girao sells $763,011 in company stock - Investing.com
Immunovant (IMVT) CFO sells 25,760 shares to cover RSU tax - Stock Titan
Immunovant (IMVT) CTO sells 2,754 shares in tax sell-to-cover - Stock Titan
Immunovant (IMVT) Innovation Pipeline | Immunovant posts 16.3% EPS beat on narrower lossRating Downgrade - Cổng thông tin điện tử tỉnh Lào Cai
Immunovant (NASDAQ:IMVT) Sets New 12-Month HighHere's What Happened - MarketBeat
How Immunovant Inc. (IMVT) Affects Rotational Strategy Timing - Stock Traders Daily
Immunovant Inc stock (US45258Q1058): Is its autoimmune pipeline strong enough to unlock new upside? - AD HOC NEWS
Immunovant: Best-In-Class Ambitions, Still Unproven (NASDAQ:IMVT) - Seeking Alpha
Immunovant Inc stock (US45258Q1058): Is its autoimmune pipeline strong enough to unlock biotech upsi - AD HOC NEWS
Immunovant (NASDAQ:IMVT) Reaches New 12-Month HighShould You Buy? - MarketBeat
Immunovant stock hits 52-week high at 29.26 USD By Investing.com - Investing.com Australia
Immunovant stock hits 52-week high at 29.26 USD - Investing.com
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.53%
자본화:
|
볼륨(24시간):